<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458416</url>
  </required_header>
  <id_info>
    <org_study_id>INS011-17-115</org_study_id>
    <nct_id>NCT03458416</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome</brief_title>
  <official_title>A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benuvia Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benuvia Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the long-term safety and tolerability of Cannabidiol&#xD;
      Oral Solution (CBD) in patients with Prader-Willi Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insys Therapeutics filed Chapter 11 and terminated all studies.&#xD;
  </why_stopped>
  <start_date type="Actual">September 6, 2018</start_date>
  <completion_date type="Actual">June 10, 2019</completion_date>
  <primary_completion_date type="Actual">June 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) Associated with Cannabidiol Oral Solution</measure>
    <time_frame>Baseline (Visit 10 of INS011-16-085) up to Visit 9 (approximately Week 52)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Change from Baseline in Vital Signs</measure>
    <time_frame>Baseline (Visit 10 of INS011-16-085) up to Visit 7 (approximately Week 48)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Change from Baseline in Physical Exam</measure>
    <time_frame>Baseline (Visit 10 of INS011-16-085) up to Visit 7 (approximately Week 48)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Change from Baseline in Electrocardiogram (ECG)</measure>
    <time_frame>Baseline (Visit 10 of INS011-16-085) up to Visit 7 (approximately Week 48)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Change from Baseline in Laboratory Values</measure>
    <time_frame>Baseline (Visit 10 of INS011-16-085) up to Visit 7 (approximately Week 48)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Change from Baseline in Weight</measure>
    <time_frame>Baseline (Visit 10 of INS011-16-085) up to Visit 7 (approximately Week 48)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Cannabidiol Oral Solution: 20-40 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol Oral Solution</intervention_name>
    <description>An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).</description>
    <arm_group_label>Cannabidiol Oral Solution: 20-40 mg/kg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completed activities up to and including Visit 10 (Study Completion) of INS011-16-&#xD;
             085.&#xD;
&#xD;
          2. Patient and/or parent(s)/caregiver(s) fully comprehend the informed consent form (ICF)&#xD;
             and assent form, understand all study procedures, and can communicate satisfactorily&#xD;
             with the investigator and study coordinator, in accordance with applicable laws,&#xD;
             regulations, and local requirements.&#xD;
&#xD;
          3. If female, is either not of childbearing potential or practicing medically acceptable&#xD;
             methods of birth control.&#xD;
&#xD;
          4. Psychotropic treatment will be permitted if the subject has been on a stable dose&#xD;
             during the INS011-16-085 and does not anticipate a dose change during the course of&#xD;
             the study.&#xD;
&#xD;
          5. Growth hormone treatment will be permitted if the subject has been on a stable dose&#xD;
             during INS01-16-085.&#xD;
&#xD;
          6. Any other treatment including thyroid hormones should be stable prior to entering the&#xD;
             INS011-17-115 study.&#xD;
&#xD;
          7. In the opinion of the investigator, the parent(s)/caregiver(s) is (are) willing and&#xD;
             able to comply with the study procedures and visit schedules, including venipuncture,&#xD;
             and the visit schedules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient or parent(s)/caregiver(s) have commitments during the study duration that&#xD;
             would interfere with attending all study visits.&#xD;
&#xD;
          2. Experienced an anoxic episode related to study drug requiring resuscitation during the&#xD;
             previous study.&#xD;
&#xD;
          3. Uncontrolled Type I and Type II Diabetes.&#xD;
&#xD;
          4. Developed an adverse event thought to be related to CBD in the previous study and the&#xD;
             investigator determines that continuing treatment with CBD would not be in the best&#xD;
             interest of the patient.&#xD;
&#xD;
          5. History of clinically significant gastrointestinal, renal, hepatic, neurologic,&#xD;
             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or&#xD;
             cardiovascular disease, or other condition which would jeopardize safety or impact&#xD;
             validity of results (per investigator).&#xD;
&#xD;
          6. Currently taking felbamate.&#xD;
&#xD;
          7. Compromised respiratory function or severe respiratory insufficiency.&#xD;
&#xD;
          8. Pregnant or lactating female..&#xD;
&#xD;
          9. In the opinion of the investigator, the patient is unsuitable in any other way to&#xD;
             participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elkashef, MD</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Research and Innovation | MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

